[8-K] Neumora Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. furnished an 8-K stating it announced financial results for the second quarter ended September 30, 2025. The full details are provided in a press release attached as Exhibit 99.1.

The company notes that the information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed under the Exchange Act. The report was signed by Chief Financial Officer Michael Milligan on November 6, 2025.

false000188552200018855222025-11-062025-11-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 06, 2025

Neumora Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41802	84-4367680
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
260 Arsenal Place, Suite 1
Watertown, Massachusetts				02472
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 857 760-0900

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		NMRA		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, Neumora Therapeutics, Inc. (“Neumora” or the “Company”) announced its financial results for the second quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished pursuant to this Item 2.02 of this Current Report on Form 8-K, including the attached Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number		Description
99.1		Press Release dated November 6, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NEUMORA THERAPEUTICS, INC.
Date:	November 6, 2025	By:	/s/ Michael Milligan
			Michael Milligan Chief Financial Officer

FAQ

What did NMRA announce in this 8-K?

Neumora announced its financial results for the second quarter ended September 30, 2025 and furnished the related press release as Exhibit 99.1.

Which period does the NMRA update cover?

The update covers the second quarter ended September 30, 2025.

Where can I find the detailed results for NMRA?

Details are in the press release furnished as Exhibit 99.1 to the 8-K.

Is the NMRA information furnished or filed?

The Item 2.02 information, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act.

Who signed the NMRA 8-K and when?

It was signed by Michael Milligan, Chief Financial Officer, on November 6, 2025.

What is NMRA’s trading symbol and exchange?

The common stock trades on The Nasdaq Global Select Market under the symbol NMRA.